{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRA&page=2", "query": { "intervention": "MRA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-12T18:00:27.468Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04077723", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Englumafusp alfa", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2019-08-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 4, "location_summary": "Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04077723" }, { "nct_id": "NCT02469896", "title": "A Trial of Tocilizumab in ALS Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALS", "Amyotrophic Lateral Sclerosis", "Lou Gehrig's Disease", "Motor Neuron Disease" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Barrow Neurological Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2015-11", "completion_date": "2018-07-11", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469896" }, { "nct_id": "NCT04808778", "title": "Stroke Prevention in Young Adults With Sickle Cell Anemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Disease", "Sickle Cell Anemia", "Stroke, Ischemic", "Silent Stroke", "Silent Cerebral Infarct", "Stroke" ], "interventions": [ { "name": "Hydroxyurea therapy per standard care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "16 Years to 26 Years" }, "enrollment_count": 250, "start_date": "2021-05-17", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04808778" }, { "nct_id": "NCT01396317", "title": "Study of Tocilizumab to Treat Polymyalgia Rheumatica", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polymyalgia Rheumatica (PMR)" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 10, "start_date": "2011-04", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396317" }, { "nct_id": "NCT01007435", "title": "A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo to tocilizumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo to methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1162, "start_date": "2009-10-31", "completion_date": "2014-01-28", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 61, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007435" }, { "nct_id": "NCT07281014", "title": "Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Spironolactone 25mg", "type": "DRUG" }, { "name": "Aldosterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2026-01-27", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281014" }, { "nct_id": "NCT03193190", "title": "A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "PEGPH20", "type": "DRUG" }, { "name": "BL-8040", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "RO6874281", "type": "DRUG" }, { "name": "AB928", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2017-07-05", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 12, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03193190" }, { "nct_id": "NCT00659776", "title": "MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nervous System Diseases", "Diagnostic Imaging" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 255, "start_date": "2004-07", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00659776" }, { "nct_id": "NCT00106535", "title": "A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1196, "start_date": "2005-01", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106535" }, { "nct_id": "NCT01783990", "title": "Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sickle Cell Anemia" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "24 Months to 18 Years" }, "enrollment_count": 150, "start_date": "2012-10", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-09-12T18:00:27.468Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01783990" } ] }